Second NICE draft still negative on Tyverb
This article was originally published in Scrip
Executive Summary
GlaxoSmithKlineproposed an access scheme that would allow patients in the national health service in England and Wales with advanced or metastatic breast cancer to be treated with free Tyverb (lapatinib) for 12 weeks, but the plan has failed to persuade the National Institute for health and Clinical Excellence(NICE) that the product is cost-effective.